Although underlying molecular mechanisms are unclear, broader trends of NNMT overexpression and its effects on treatment resistance in a variety of cancer cell lines, including gastric cancer and OSCC, warrants further investigation into NNMT’s role in facilitating treatment resistance in OAC and its potential as a biomarker to predict NAT response [82,83]. The gene discussed is BRD2; the disease is gastric cancer.